32 results
8-K
EX-99.2
ANNX
Annexon Inc
20 Dec 23
Regulation FD Disclosure
5:17pm
complement inhibitor that we believe can have meaningful impact on a range of autoimmune conditions,” said Ted Yednock, Ph.D., chief innovation officer
8-K
EX-99.1
l2g7jh3mv rqqghg
9 Nov 21
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
4:16pm
8-K
EX-99.1
z6npt3a 6mnb
4 Oct 21
Departure of Directors or Certain Officers
4:06pm
8-K
0exfw7g gchy8a2am87
4 Oct 21
Departure of Directors or Certain Officers
4:06pm
DEF 14A
n1uvi5p3zmq ubxtk1hp
22 Apr 21
Definitive proxy
4:06pm